Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
16
HKPD Quote, Financials, Valuation and Earnings
Last price:
$0.71
Seasonality move
:
--
Day range:
$0.72 - $0.76
52-week range:
$0.68 - $3.79
Dividend yield:
0%
P/E ratio:
8.18x
P/S ratio:
0.75x
P/B ratio:
2.30x
Volume:
26.3K
Avg. volume:
174.3K
1-year change:
--
Market cap:
$8.2M
Revenue:
$16.7M
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | -- | -- | $22.58 |
|
PRE
Prenetics Global Ltd.
|
$26M | -- | 265.18% | -- | $26.00 |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
$0.75 | -- | $8.2M | 8.18x | $0.00 | 0% | 0.75x |
|
HCM
HUTCHMED (China) Ltd.
|
$13.52 | $22.58 | $2.3B | 5.04x | $0.00 | 0% | 3.91x |
|
PRE
Prenetics Global Ltd.
|
$16.91 | $26.00 | $284.6M | -- | $0.00 | 0% | 3.29x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
$24.60 | -- | $12.2B | -- | $0.00 | 0% | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
$18.22 | -- | $16.3B | 31.84x | $0.13 | 1.26% | 3.87x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
-- | 0.000 | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
7.07% | 0.509 | -- | 4.41x |
|
PRE
Prenetics Global Ltd.
|
1.29% | 4.220 | 1.18% | 1.01x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | 21.200 | -- | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
23.1% | -0.180 | -- | 1.14x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
-- | -- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | 46.32% | 50.64% | -- | -- |
|
PRE
Prenetics Global Ltd.
|
$14M | -$6.6M | -26.04% | -26.74% | -27.85% | -- |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
-- | -- | 6.83% | 8.57% | -- | -- |
Hong Kong Pharma Digital Technology Holdings Ltd. vs. Competitors
-
Which has Higher Returns HKPD or HCM?
HUTCHMED (China) Ltd. has a net margin of -- compared to Hong Kong Pharma Digital Technology Holdings Ltd.'s net margin of --. Hong Kong Pharma Digital Technology Holdings Ltd.'s return on equity of -- beat HUTCHMED (China) Ltd.'s return on equity of 50.64%.
Company Gross Margin Earnings Per Share Invested Capital HKPDHong Kong Pharma Digital Technology Holdings Ltd.-- -- -- HCMHUTCHMED (China) Ltd.-- -- $1.3B -
What do Analysts Say About HKPD or HCM?
Hong Kong Pharma Digital Technology Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand HUTCHMED (China) Ltd. has an analysts' consensus of $22.58 which suggests that it could grow by 67.05%. Given that HUTCHMED (China) Ltd. has higher upside potential than Hong Kong Pharma Digital Technology Holdings Ltd., analysts believe HUTCHMED (China) Ltd. is more attractive than Hong Kong Pharma Digital Technology Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HKPDHong Kong Pharma Digital Technology Holdings Ltd.0 0 0 HCMHUTCHMED (China) Ltd.9 2 1 -
Is HKPD or HCM More Risky?
Hong Kong Pharma Digital Technology Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HUTCHMED (China) Ltd. has a beta of 0.416, suggesting its less volatile than the S&P 500 by 58.402%.
-
Which is a Better Dividend Stock HKPD or HCM?
Hong Kong Pharma Digital Technology Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HUTCHMED (China) Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hong Kong Pharma Digital Technology Holdings Ltd. pays -- of its earnings as a dividend. HUTCHMED (China) Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HKPD or HCM?
Hong Kong Pharma Digital Technology Holdings Ltd. quarterly revenues are --, which are smaller than HUTCHMED (China) Ltd. quarterly revenues of --. Hong Kong Pharma Digital Technology Holdings Ltd.'s net income of -- is lower than HUTCHMED (China) Ltd.'s net income of --. Notably, Hong Kong Pharma Digital Technology Holdings Ltd.'s price-to-earnings ratio is 8.18x while HUTCHMED (China) Ltd.'s PE ratio is 5.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hong Kong Pharma Digital Technology Holdings Ltd. is 0.75x versus 3.91x for HUTCHMED (China) Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HKPDHong Kong Pharma Digital Technology Holdings Ltd.0.75x 8.18x -- -- HCMHUTCHMED (China) Ltd.3.91x 5.04x -- --
-
Which has Higher Returns HKPD or PRE?
Prenetics Global Ltd. has a net margin of -- compared to Hong Kong Pharma Digital Technology Holdings Ltd.'s net margin of -28.82%. Hong Kong Pharma Digital Technology Holdings Ltd.'s return on equity of -- beat Prenetics Global Ltd.'s return on equity of -26.74%.
Company Gross Margin Earnings Per Share Invested Capital HKPDHong Kong Pharma Digital Technology Holdings Ltd.-- -- -- PREPrenetics Global Ltd.59.54% -$0.53 $163.3M -
What do Analysts Say About HKPD or PRE?
Hong Kong Pharma Digital Technology Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Prenetics Global Ltd. has an analysts' consensus of $26.00 which suggests that it could grow by 83.32%. Given that Prenetics Global Ltd. has higher upside potential than Hong Kong Pharma Digital Technology Holdings Ltd., analysts believe Prenetics Global Ltd. is more attractive than Hong Kong Pharma Digital Technology Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HKPDHong Kong Pharma Digital Technology Holdings Ltd.0 0 0 PREPrenetics Global Ltd.1 0 0 -
Is HKPD or PRE More Risky?
Hong Kong Pharma Digital Technology Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Prenetics Global Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HKPD or PRE?
Hong Kong Pharma Digital Technology Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prenetics Global Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hong Kong Pharma Digital Technology Holdings Ltd. pays -- of its earnings as a dividend. Prenetics Global Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HKPD or PRE?
Hong Kong Pharma Digital Technology Holdings Ltd. quarterly revenues are --, which are smaller than Prenetics Global Ltd. quarterly revenues of $23.6M. Hong Kong Pharma Digital Technology Holdings Ltd.'s net income of -- is lower than Prenetics Global Ltd.'s net income of -$6.8M. Notably, Hong Kong Pharma Digital Technology Holdings Ltd.'s price-to-earnings ratio is 8.18x while Prenetics Global Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hong Kong Pharma Digital Technology Holdings Ltd. is 0.75x versus 3.29x for Prenetics Global Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HKPDHong Kong Pharma Digital Technology Holdings Ltd.0.75x 8.18x -- -- PREPrenetics Global Ltd.3.29x -- $23.6M -$6.8M
-
Which has Higher Returns HKPD or RGC?
Regencell Bioscience Holdings Ltd. has a net margin of -- compared to Hong Kong Pharma Digital Technology Holdings Ltd.'s net margin of --. Hong Kong Pharma Digital Technology Holdings Ltd.'s return on equity of -- beat Regencell Bioscience Holdings Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HKPDHong Kong Pharma Digital Technology Holdings Ltd.-- -- -- RGCRegencell Bioscience Holdings Ltd.-- -- -- -
What do Analysts Say About HKPD or RGC?
Hong Kong Pharma Digital Technology Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Regencell Bioscience Holdings Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Hong Kong Pharma Digital Technology Holdings Ltd. has higher upside potential than Regencell Bioscience Holdings Ltd., analysts believe Hong Kong Pharma Digital Technology Holdings Ltd. is more attractive than Regencell Bioscience Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HKPDHong Kong Pharma Digital Technology Holdings Ltd.0 0 0 RGCRegencell Bioscience Holdings Ltd.0 0 0 -
Is HKPD or RGC More Risky?
Hong Kong Pharma Digital Technology Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regencell Bioscience Holdings Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HKPD or RGC?
Hong Kong Pharma Digital Technology Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regencell Bioscience Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hong Kong Pharma Digital Technology Holdings Ltd. pays -- of its earnings as a dividend. Regencell Bioscience Holdings Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HKPD or RGC?
Hong Kong Pharma Digital Technology Holdings Ltd. quarterly revenues are --, which are smaller than Regencell Bioscience Holdings Ltd. quarterly revenues of --. Hong Kong Pharma Digital Technology Holdings Ltd.'s net income of -- is lower than Regencell Bioscience Holdings Ltd.'s net income of --. Notably, Hong Kong Pharma Digital Technology Holdings Ltd.'s price-to-earnings ratio is 8.18x while Regencell Bioscience Holdings Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hong Kong Pharma Digital Technology Holdings Ltd. is 0.75x versus -- for Regencell Bioscience Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HKPDHong Kong Pharma Digital Technology Holdings Ltd.0.75x 8.18x -- -- RGCRegencell Bioscience Holdings Ltd.-- -- -- --
-
Which has Higher Returns HKPD or SBHMY?
Sino Biopharmaceutical Ltd. has a net margin of -- compared to Hong Kong Pharma Digital Technology Holdings Ltd.'s net margin of --. Hong Kong Pharma Digital Technology Holdings Ltd.'s return on equity of -- beat Sino Biopharmaceutical Ltd.'s return on equity of 8.57%.
Company Gross Margin Earnings Per Share Invested Capital HKPDHong Kong Pharma Digital Technology Holdings Ltd.-- -- -- SBHMYSino Biopharmaceutical Ltd.-- -- $7.2B -
What do Analysts Say About HKPD or SBHMY?
Hong Kong Pharma Digital Technology Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sino Biopharmaceutical Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Hong Kong Pharma Digital Technology Holdings Ltd. has higher upside potential than Sino Biopharmaceutical Ltd., analysts believe Hong Kong Pharma Digital Technology Holdings Ltd. is more attractive than Sino Biopharmaceutical Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HKPDHong Kong Pharma Digital Technology Holdings Ltd.0 0 0 SBHMYSino Biopharmaceutical Ltd.0 0 0 -
Is HKPD or SBHMY More Risky?
Hong Kong Pharma Digital Technology Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sino Biopharmaceutical Ltd. has a beta of 0.555, suggesting its less volatile than the S&P 500 by 44.514%.
-
Which is a Better Dividend Stock HKPD or SBHMY?
Hong Kong Pharma Digital Technology Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sino Biopharmaceutical Ltd. offers a yield of 1.26% to investors and pays a quarterly dividend of $0.13 per share. Hong Kong Pharma Digital Technology Holdings Ltd. pays -- of its earnings as a dividend. Sino Biopharmaceutical Ltd. pays out 55.99% of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HKPD or SBHMY?
Hong Kong Pharma Digital Technology Holdings Ltd. quarterly revenues are --, which are smaller than Sino Biopharmaceutical Ltd. quarterly revenues of --. Hong Kong Pharma Digital Technology Holdings Ltd.'s net income of -- is lower than Sino Biopharmaceutical Ltd.'s net income of --. Notably, Hong Kong Pharma Digital Technology Holdings Ltd.'s price-to-earnings ratio is 8.18x while Sino Biopharmaceutical Ltd.'s PE ratio is 31.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hong Kong Pharma Digital Technology Holdings Ltd. is 0.75x versus 3.87x for Sino Biopharmaceutical Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HKPDHong Kong Pharma Digital Technology Holdings Ltd.0.75x 8.18x -- -- SBHMYSino Biopharmaceutical Ltd.3.87x 31.84x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
